NATALIE WONG: Open Payments
NPI 1619751930 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,959 in 191 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $1,038 · 2025 $5,959
Food & beverage: $5,959
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $820 |
| Vanda Pharmaceuticals Inc. | 25 | $789 |
| Otsuka America Pharmaceutical, Inc. | 21 | $643 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $501 |
| E.R. Squibb & Sons, L.L.C. | 19 | $489 |
| Janssen Pharmaceuticals, Inc | 9 | $423 |
| Neurocrine BioSciences, Inc. | 15 | $400 |
| Axsome Therapeutics, Inc. | 9 | $334 |
| Biogen, Inc. | 9 | $306 |
| Teva Pharmaceuticals USA, Inc. | 16 | $305 |
Products named: VRAYLAR, FANAPT, CAPLYTA, COBENFY, REXULTI, INGREZZA, Auvelity, ZURZUVAE.
Industry payments across CA — which companies pay providers there.
